

NCIC CLINICAL TRIALS GROUP

**GYNECOLOGY**

DISEASE SITE COMMITTEE MEETING  
AGENDA

Hilton Montréal Bonaventure, Montréal, Québec  
Saturday, April 29, 2006 - 8:30 a.m. - 3:30 p.m.  
Room: Lachine/Lasalle

Chairs: Gavin Stuart & Amit Oza

- 
- |            |  |                            |
|------------|--|----------------------------|
| 8:30 a.m.  | <b><u>WELCOME AND INTRODUCTION</u></b> (20 min)                              | G. Stuart                  |
|            | Approval of Minutes (April and October 2005)                                 |                            |
|            | Additions to agenda  | All                        |
|            | New working group on correlative studies and tumour banking                  | A. Oza                     |
|            | GCIG report & representation   | G. Stuart                  |
| 8:50 a.m.  | <b><u>OVARIAN CANCER</u></b> (3 hrs)   |                            |
|            | <u>Closed Studies</u> : Update on analysis timelines for information (5 min) | E. Eisenhauer              |
|            | <u>Open Studies</u> (20 min):  |                            |
|            | NCIC CTG OV.13 (EORTC 55971) report  | G. Stuart                  |
|            | NCIC CTG OV.16 report  | P. Hoskins/E. Eisenhauer   |
|            | OV.16 translational research plans   | TBD                        |
|            | NCIC CTG OV.17   | M. Heywood                 |
|            | Discussion   | All                        |
|            | <u>Planned Studies</u> (2 hrs)   |                            |
|            | First line – ICON7/OV.19   | A.M. Swart/M. Carey/A. Oza |
|            | Recurrent disease ICON6/OV.18  | A.M. Swart/H. Hirte        |
|            | Clear Cell Carcinoma Trial (JGOG)/OV.20                                      | S. Ellard                  |
|            | <b>BREAK</b> for coffee midway through planned studies                       |                            |
|            | <u>Proposals</u> (40 min)  | Discussion/All             |
|            | IP: GOG and MRC plans  |                            |
|            | AGO Desktop study  |                            |
|            | Other  |                            |
| 12:00 p.m. | <b>LUNCH</b>   |                            |

*continued . . .*

- 1:30 p.m.      **REPORTS/UPDATES** (30 min)
- SCRN      Z. Rosberger  
QoL (report here updates on the various QoL Projects):  
Pharmacist      N. May  
CRA      H. Harris  
Pathology      M. McLachlin  
Economics      L. Elit  
Lay      M. Manojivich  
IND (closed/opened/planned NCIC CTG IND trials not presented elsewhere)      H. Hirte
- 2:00 p.m.      **ENDOMETRIAL CANCER** (45 min)      K. Swenerton
- NCIC CTG EN5 - (5 min) status report + ASTEC (MRC)      A.M. Swart/T. Whelan  
Molecular Biology      A. Oza  
CCI-779 studies:      NCIC CTG IND.160 report (10 min)      A. Oza  
Proposal for two randomized GCIC trials (30min)      A. Oza  
Endometrial WG teleconference report      K. Swenerton
- 2:45 p.m.      **CERVICAL CANCER** (25 min)      L. Souhami
- CXC1 GOG Tirapazamine study (formerly called CX.5)      P. Craighead  
Working Group/Future directions: teleconference report      L. Souhami  
Metastatic Disease Trials      A. Oza/H. Hirte
- 3:10 p.m.      **VULVAR CANCER** (10 min)
- Proposals from gyne committee members (circulated in advance)
- 3:20 p.m.      **G.T.D.** (10 min)
- NCIC CTG GT.1 (GOG 174) Report      R. Osbourne/D. Provencher
- 3:30 p.m.      **ADJOURN**
- 3:35 p.m      **EXECUTIVE SESSION**